EXPRESSION STREAM
2nd Annual
Optimizing Protein Expression May 2 - 3
Day 1 | Day 2 | Download Brochure
WEDNESDAY, MAY 2
7:00 am Registration and Morning Coffee
8:30 Chairperson’s Opening Remarks
» 8:40 Keynote Presentation
Approaches to Maximize Protein Expression for Discovery and Development Efforts
 William H. Brondyk, Ph.D., Senior Scientific Director, Therapeutic Protein Discovery, Genzyme – A Sanofi Company (biography)
Achieving sufficient expression levels of recombinant proteins to meet the needs for both discovery and development efforts are a goal for biotechnology and pharmaceutical companies. In this talk, a description of our currently used insect and mammalian expression systems will be presented. Specific information will be discussed regarding our optimization of vectors, strategy for the selection of the expression system, methods for generating high expressing CHO pools and clones, and gene design.
|
» 9:10 FEATURED PRESENTATION
Transient Expression of Proteins in HEK293 and CHO Cells –
or is There an Alternative?
 Sabine Geisse, Ph.D., Director, NLS, Novartis Pharma AG (biography)
We describe a novel cell line, CAP-T® derived from human amniocytes, as host in transient protein production, and the establishment of suitable protocols for transfection and expression of recombinant proteins. Moreover, we show comparative analyses of expression to the well-known HEK293 and CHO transient protein production platforms. In brief, the addition of the CAP-T® cells to the repertoire of cell lines amenable to transient protein production clearly enhances the chances of success.
|
9:40 Transient (HEK293) and Stable (CHO) Expression of Dual Variable Domain (DVD) - Ig™ Molecules
Tariq Ghayur, Ph.D., Senior Principal Scientist & Research Fellow, Biologics, Abbott Bioresearch Center, Inc. (biography)
10:10 Coffee Break in the Exhibit Hall with Poster Viewing
11:10 An Update on the International Community’s Efforts at CHOgenome.org
Kelvin H. Lee, Gore Professor of Chemical Engineering & Director, Delaware Biotechnology Institute, University of Delaware (biography)
Today, a quarter of all FDA approved new drugs are biopharmaceuticals, most of which are produced in Chinese hamster ovary (CHO) cells. The CHO K1 cell line is an ancestor to many production cell lines and was recently fully sequenced. We will discuss the aspects of the international community’s efforts at developing an infrastructure to support, host, and disseminate genome-scale data related to CHO cell lines.
11:40 Dynamic Model for CHO Cell Engineering
Kyongbum Lee, Ph.D., Associate Professor & Acting Chair, Chemical and Biological Engineering, Tufts University (biography)
CHO cell fed-batch processes have progressed significantly over the past decade, with protein titer consistently reaching the gram per liter level. Progress has largely resulted from separate advances in process and cell line development. We use a dynamic model to explore~104 combinations of process and cell modifications. Knockdowns in glycolysis were the most beneficial; however, depending on the process conditions, such knockdowns could reduce the antibody titer. Our results highlight the need to consider process and cell modifications together.
12:10 pm Luncheon Presentation (Sponsorship Opportunities Available) or Lunch on Your Own
1:30 Chairperson’s Remarks
1:35 Maximizing Production of Soluble IL-15: Cytokine Receptor Superagonist Complexes by CHO Cells
Peter Rhode, Ph.D., Vice President, R&D, Altor BioScience Corp. (biography)
Interleukin-15 is a promising immunostimulatory cytokine for treatment of cancer and viral diseases. However, its development has been limited by poor expression in bacterial and mammalian systems. We have found that co-expression of an IL-15 superagonist variant with a soluble IL-15 receptor alpha - IgG1 Fc fusion leads to high level production of a fully active IL-15:IL-15Rα complex by CHO cells. A simple, scalable affinity and ion exchange chromatography method was conducted to highly purify this complex, enabling its clinical development.
2:05 The Microalgal Cell Line PTA: A Novel Host for the Expression of Therapeutic Glycosylated Proteins
Aude Carlier, Ph.D., Co-Founder, President & CSO, Algenics (biography)
The increasing importance of biologics as well as knowledge gained from decades of therapies led to challenges and opportunities in the field of biomanufacturing. The technological platform AlgebiosysTM developed by Algenics leverages microalgae capabilities to achieve consistent and qualitative glycoproteins expression. To demonstrate the versatility offered by our microalgal cell line, proofs of concept including monoclonal antibodies and recombinant viral antigens will be presented with emphasis on glycosylation properties.
Sponsored by
2:35 Transient Gene Expression: So You’re Already Using PEI (polyethylenimine) – What Could be Better?
Habib Horry, Ph.D., Strategic Marketing Manager, Polypus-transfection
With 10 years of “PEI for transfection” manufacturing experience, Polyplus-transfection® introduces the last generation of PEI for cost effective production of milligrams to grams amount of r-proteins in suspension-adapted mammalian cell lines.
Sponsored by
2:50 Sponsored Presentation
To be Announced
3:05 Refreshment Break in the Exhibit Hall with Poster Viewing
3:50 Problem Solving Breakout Discussions
Concurrent problem solving breakout discussions, open to all attendees, speakers, sponsors, and exhibitors, provide a forum for discussing key issues and meeting potential collaborators. Plan to take part and explore these topics in-depth. Please pick a topic of your choice, find your table and join in.
Transient Protein Expression – Where Do We Go In The Future?
Moderator: Sabine Geisse, Ph.D., Director, NLS, Novartis Pharma AG
• Advantages and drawbacks/bottlenecks of current processes
• Ways to improve expression rates and processes
• Can transient expression replace GMP-conform manufacturing cell lines in the future?
• What would be needed to develop and implement above mentioned application of transient production?
4:50-6:00 Networking Reception in the Exhibit Hall with Poster Viewing
Day 1 | Day 2 | Download Brochure